Patent intelligence · US
US 11759461
Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
Patent details — US 11759461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 19, 2023
- Expiration
- Sep 14, 2043
- Claims
- 1
- CPC classes
- A61K, A61K31/437, A61K31/4704, A61K31/4741
Quick answer
US 11759461 (Small molecule inhibitors of cancer stem cells and mesenchymal cancer types) is held by THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS. Status: granted. Granted Sep 19, 2023. Expires Sep 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61K, A61K31/437, A61K31/4704, A61K31/4741, A61K31/497, A61K31/498
More from THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11759461?
US 11759461 (Small molecule inhibitors of cancer stem cells and mesenchymal cancer types) is held by THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS. Status: granted. Granted Sep 19, 2023. Expires Sep 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11759461?
THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11759461 expire?
Our index shows an expiration date of Sep 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.